Colinz Laboratories Ltd
BSE:531210
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
C
|
Colinz Laboratories Ltd
BSE:531210
|
120.4m INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Colinz Laboratories Ltd
Glance View
Colinz Laboratories Ltd. engages in the manufacture of pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectable, ointments, and creams. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2004-01-13. The firm operates and supplies medicines in the domestic market. The Company’s products include oncology, ayurvedic and nutraceuticals. Its oncology products include imatinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim and pegylated liposome doxorubicin. Its ayurvedic products include anti-diarrheas, anti-pyrectics, anti-inflammatories, anti-spasmodic, cough syrups, appetite stimulating agents, memory boosters, anti-piles, antacids, liver tonic, ulcer healing agents, digestive agents, drugs to treat oligospermia and erectile dysfunction, ear drops, uterine tonic, anti-diabetics, and general tonics.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Colinz Laboratories Ltd is 72%, which is above its 3-year median of 68.6%.
Over the last 3 years, Colinz Laboratories Ltd’s Gross Margin has increased from 67.7% to 72%. During this period, it reached a low of 67% on Jun 30, 2024 and a high of 72.2% on Sep 30, 2025.
